Table 2. Intervention characteristics, clinical outcomes, and adverse events.

	n = 49
Technical success rate	100 %
Clinical success rate	87.8 %
Mortality	8.2 %
Period until intervention (d) median (95 % CI)	7 (3–11)
necrosectomies	4 (3–5)
ICU treatment, n (%)	21(43 %)
ICU days, median (95 %CI)	5 (3–9)
IMC treatment, n (%)	33 (67 %)
IMC days, median (95 %CI)	3(2–4)
Follow-up(months), median (95 %CI)	14 (10–18)
CRP pre (mg/L), median (95 %CI)	241 (182.8–288.9)
CRP post (mg/L), median (95 %CI)	23.3(18–60)
WBC pre (T/µL), median (95 %CI)	15.1(13.6–17.5)
WBC post (T/µL), median (95 %CI)	7.9(6.5–9.3)
Adverse events	6 (12.2 %)
Bleeding	2 (4.1 %)
Perforation	2 (4.1 %)
Dislocation	4 (8.2 %)

ICU, intensive care unit; IMC, intermediate care unit; CRP, C-reactive protein; WBC, white blood cell.